Medical Advocates
Emtricitabine(Emtriva)
 
Main Page

New and Noteworthy
Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)
FDA Updates
Guidelines
Journal Citations
Conference Citations
Pediatric Indications
Perinatal Indications


 

  
ARV Drugs Main Page Main New/Newsworthy Home Page      
This web page is best viewed by using INTERNET EXPLORER
Last Update:  May 10, 2008  
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
March 2008
 
FDA Updates
 
Pediatric Indications
 
USPHS Pediatric Antiretroviral Drug Information
US Treatment Guidelines
 
Pharmacokinetics

          Journal Papers, Abstracts, and Commentaries
 
 
Long-term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine,
and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS
Clinical Trials Group Protocol P1021.
McKinney RE, Rodman J, Hu C
Pediatrics. 2007 Jul 23;
 Abstract

Pharmacokinetics and Safety of Single Oral Doses of Emtricitabine in Human
Immunodeficiency Virus-Infected Children.
Wang LH, Wiznia AA, Rathore MH, et al.
Antimicrob Agents Chemother. 2004 Jan;48(1):183-191
 Abstract
 
         Conference Reports, Abstracts, and Posters
 
 

Extended Follow-up and Pharmacokinetics for Once Daily Emtricitabine, Didanosine,
and Efavirenz for Antiretroviral Naïve Children and Adolescents
 R McKinney, J Rodman, M Rathore, et al  
(11 CROI)
 Abstract
 
Efficacy
 
          Journal Papers, Abstracts, and Commentaries
 
 
Long-term Safety and Efficacy Results of Once-Daily Emtricitabine-Based Highly Active
Antiretroviral Therapy Regimens in Human Immunodeficiency Virus-Infected Pediatric Subjects.
 Saez-Llorens X, Violari A, Ndiweni D, et al 
Pediatrics. 2008 Mar 10
 Abstract

Long-term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and
Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical
Trials Group Protocol P1021.
McKinney RE, Rodman J, Hu C
Pediatrics. 2007 Jul 23;
 Abstract
 
         Conference Reports, Abstracts, and Posters
 
 
A Phase I/II Study of a Once-daily Regimen of Emtricitabine, Didanosine, and
Efavirenz in HIV-infected, Therapy-naïve Children and Adolescents
Mathore, R McKinney, C Hu, et al
 (15th CROI
 Abstract
 
Virologic and Immunologic Correlates of Immune Reconstitution in HIV-infected Children on
FTC/DDI/EFV: PACTG Protocol P1021
A Weinberg, P Britto, C Hu, et al 
(13 CROI)
 Abstract
 
Phase I/II Study of a Once-daily Regimen of Emtricitabine, Didanosine, and Efavirenz in
HIV-infected, Therapy-naïve Children and Adolescents: PACTG Protocol 1021
R McKinney, M Rathore, C Hu, et al
 (13 CROI)
 Abstract

Once daily (QD) emtricitabine (FTC) with other antiretroviral agents (ART) in
HIV-infected pediatric patients at 48 weeks
A Wiznia, A Violari, D Ndiweni,  et al
(15IAC)
 Abstract
Perinatal Indications
 
     Internet Documents
 
  FULL TEXT PDF DOCUMENT
 Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  PDF DOCUMENT
 Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
         Conference Reports, Abstracts, and Posters
 
 
Population Pharmacokinetics of Emtricitabine in HIV-infected Pregnant Women and
Their Neonates: Temaa ANRS 12109
D Hirt, S Urien, E Rey, et al
(15th CROI)
 Abstract

POSTER
 Steady-state Pharmacokinetic Evaluation of Emtricitabine in Neonates Exposed to HIV in utero
 MR Blum, D Ndiweni, G Chittick, et al
(13 CROI)
 PDF Poster     Abstract

ARV Drugs Main Page Main New/Newsworthy Home Page      

Emtricitabine Main Page